Drugs / CG-105-12
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 0 | NCT06999031 | Sep 2024 → Apr 2026 overdue | plasma cell myeloma | The First Affiliated Hospital of Nanchang University | Recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | CG-105-12 | “A Study to Evaluate CG-105-12 in Patients With Relapsed/Refractory Multiple Myeloma” NCT06999031 ↗ |
| Modality | Cell therapy | “Chimeric Antigen Receptor Autologous T-cell” NCT06999031 ↗ |